SCHEMBL3010819

SCHEMBL3010819

Cc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3cccc(Cl)c3Cl)CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
LMNA P02545 3/20 0.52
MAPT P10636 3/20 0.52
MEN1 O00255 2/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPK1 P28482 2/20 0.48
TSHR P16473 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
TP53 P04637 1/20 0.43
AR P10275 2/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SPR P35270 1/20 0.42
RAB9A P51151 2/20 0.41
GBA1 P04062 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008326 0.93 LMNA (0.48) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3002043 0.93 KMT2A (0.52) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3008564 0.90 KMT2A (0.51) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3008907 0.89 AR (0.56) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3015116 0.88 KMT2A (0.52) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3012617 0.87 LMNA (0.52) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3022481 0.86 LMNA (0.48) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3011363 0.85 LMNA (0.51) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3012392 0.85 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2LMNAMAPTMEN1
SCHEMBL3005738 0.85 LMNA (0.64) KMT2ASMN1; SMN2LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885SMN1; SMN2 1/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.